Quadrature Capital
TRDA icon

Quadrature Capital’s Entrada Therapeutics TRDA Stock Holding History

Quadrature Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.6K Sell
13,257
-4,281
-24% -$41.1K ﹤0.01% 1470
2026
Q1 		$221K Sell
17,538
-2,780
-14% -$31.9K ﹤0.01% 1084
2025
Q4 		$209K Buy
20,318
+2,424
+14% +$20.4K ﹤0.01% 961
2025
Q3 		$103K Buy
+17,894
New +$105K ﹤0.01% 868

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Quadrature Capital's TRDA Position: Q2 2026 in Review

Quadrature Capital reduced its Entrada Therapeutics (TRDA) stake by 24% in Q2 2026, selling an estimated $41.1K and leaving 13,257 shares worth $97.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

Quadrature Capital first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $221K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Quadrature Capital held 13,257 shares of Entrada Therapeutics worth $97.6K as of Q2 2026.
  • Quadrature Capital sold 4,281 Entrada Therapeutics shares in Q2 2026, an estimated $41.1K.
  • Entrada Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1470 holding.
  • Quadrature Capital first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Entrada Therapeutics position peaked at $221K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.